Physician profile
Donald E Steely
NPI 1700855921
$9,553.38
in general payments reported to CMS, 2019-2025
30 companies · $709 in 2025
The $709 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,288 · 2020: $299 · 2021: $454 · 2022: $898 · 2023: $961 · 2024: $944 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.34 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,110.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,282.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $441.26 | 2022-2025 | Verquvo |
| Pfizer INC. | $431.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $393.33 | 2019-2024 | Xarelto |
| Amgen INC. | $368.45 | 2019-2023 | Repatha |
| Actelion Pharmaceuticals US, INC. | $300.34 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Sanofi-Aventis U.S. LLC | $263.36 | 2019-2024 | |
| Medtronic, INC. | $250.40 | 2022-2025 | Azure Xt Dr Mri Surescan, Symplicity G3, Launcher |
| Astrazeneca Pharmaceuticals LP | $249.30 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $201.83 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $188.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.71 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $131.63 | 2019-2021 | |
| Boston Scientific Corporation | $115.71 | 2021-2025 | Watchman, Eluvia, Watchman Access System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $93.03 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $87.88 | 2021-2023 | Mitraclip |
| Novo Nordisk INC | $81.88 | 2024-2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $70.26 | 2024 | Inpefa |
| Abiomed | $65.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.31 | 2021-2023 | |
| Cathworks, INC. | $38.57 | 2025 | Ffrangio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.42 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $31.17 | 2024 | Arcalyst |
| Shockwave Medical, INC | $25.10 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cook Medical LLC | $22.83 | 2019 | |
| Philips North America LLC | $17.06 | 2025 | Extended Holter |
| Siemens Medical Solutions USA, INC. | $16.43 | 2019 | |
| Cashflow Solutions, LLC | $14.81 | 2023 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Gilead Sciences, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Steely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.